The specter of generic rivalry has long loomed above copyright’s famous drug, PDE5 Inhibitor, sparking questions about the future of connected drug portfolios. While first periods saw impressive profits, the exclusivity lapse has created the door for less expensive substitutes, potentially diminishing earnings and presenting a real hazard for sha